BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Crestline Management LP

Crestline Management LP raised its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 33.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 44,740 shares of the company's stock after buying an additional 11,169 shares during the period. Crestline Management LP's holdings in BridgeBio Pharma were worth $1,228,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BBIO. Barclays PLC boosted its holdings in BridgeBio Pharma by 31.9% in the 3rd quarter. Barclays PLC now owns 545,008 shares of the company's stock worth $13,876,000 after buying an additional 131,743 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company's stock worth $29,155,000 after buying an additional 19,978 shares during the last quarter. Avanza Fonder AB acquired a new stake in BridgeBio Pharma in the 4th quarter worth about $181,000. Moss Adams Wealth Advisors LLC acquired a new stake in BridgeBio Pharma in the 4th quarter worth about $208,000. Finally, Atomi Financial Group Inc. acquired a new stake in BridgeBio Pharma in the 4th quarter worth about $392,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on BBIO. HC Wainwright lifted their price objective on BridgeBio Pharma from $49.00 to $53.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. UBS Group boosted their target price on BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday, April 30th. Scotiabank boosted their target price on BridgeBio Pharma from $52.00 to $55.00 and gave the stock a "sector outperform" rating in a report on Wednesday, April 30th. JPMorgan Chase & Co. boosted their target price on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a report on Monday, March 24th. Finally, Redburn Atlantic assumed coverage on BridgeBio Pharma in a report on Monday, March 31st. They set a "buy" rating and a $50.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, BridgeBio Pharma currently has an average rating of "Moderate Buy" and an average target price of $57.09.

Insider Buying and Selling at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,148 shares of the company's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total transaction of $149,991.68. Following the sale, the chief financial officer now owns 102,464 shares of the company's stock, valued at approximately $3,705,098.24. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Maricel Apuli sold 1,026 shares of the stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $38.51, for a total value of $39,511.26. Following the completion of the transaction, the chief accounting officer now directly owns 147,639 shares in the company, valued at $5,685,577.89. This trade represents a 0.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,410,217 shares of company stock valued at $212,434,332 over the last quarter. 24.66% of the stock is owned by company insiders.

BridgeBio Pharma Price Performance

BBIO traded down $2.42 during trading hours on Tuesday, reaching $33.26. The company's stock had a trading volume of 6,368,922 shares, compared to its average volume of 2,421,050. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $39.54. The stock has a market cap of $6.32 billion, a PE ratio of -11.67 and a beta of 1.15. The business's 50-day moving average is $34.29 and its 200-day moving average is $31.38.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.12. The firm had revenue of $36.74 million during the quarter, compared to analysts' expectations of $57.14 million. The firm's revenue for the quarter was down 44.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.20) EPS. Analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.